Literature DB >> 6087783

Hormone receptors in male breast cancer.

R J Mercer, R M Bryan, R C Bennett.   

Abstract

Hormone receptor assays were performed on specimens of breast cancer from 19 male patients over a six year period. Ninety-four per cent were positive for oestrogen receptor, 93% for progesterone receptor and 57% for androgen receptor. Eight patients had hormonal treatment for advanced disease and five (62.5%) responded. Duration of response ranged from six months to 23 months. There appeared to be no clear relationship between hormone receptor status or quantitative receptor level and response to treatment in this small series. It is unlikely that oestrogen and progesterone receptors will be of value as discriminators because of their high incidence and it is suggested that further study of androgen receptor is indicated.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6087783     DOI: 10.1111/j.1445-2197.1984.tb05305.x

Source DB:  PubMed          Journal:  Aust N Z J Surg        ISSN: 0004-8682


  3 in total

Review 1.  Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  M M Buckley; K L Goa
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

Review 2.  Estrogen receptor content in malignant breast tumors in men--a review.

Authors:  H Olsson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-07       Impact factor: 2.673

3.  Androgen receptor expression in male breast carcinoma: lack of clinicopathological association.

Authors:  A Pich; E Margaria; L Chiusa; G Candelaresi; O Dal Canton
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.